Senzime and Philips Medical Systems Enter Development and Commercialization Partnership

Rhea-AI Summary

Senzime (OTCQX:SNZZF, STO:SEZI) has entered into a long-term development and commercialization agreement with Philips Electronics Nederland B.V. through Philips Hospital Patient Monitoring, a global provider of patient monitoring systems. The partnership will explore and develop future solutions that combine the companies’ proprietary technologies and target market segments that complement Senzime’s existing products and sales channels.

According to Senzime, any resulting solutions will be commercialized via Philips’ global organization, while being managed within Senzime alongside its current portfolio. The company stated that the agreement is expected to broaden its reach to tens of thousands of hospitals and create new revenue streams over the medium to long term. Senzime noted its monitoring solutions have already been used on more than one million patients and are currently sold directly in the United States and Germany and via distribution and license partners in over 30 additional countries.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

• Long-term partnership with Philips Hospital Patient Monitoring to co-develop and commercialize new solutions
• Commercialization through Philips’ global organization expected to open access to tens of thousands of hospitals
• Complementary to existing strategy, managed alongside Senzime’s current product portfolio and channels
• Existing installed base of more than one million monitored patients across 30+ countries provides proof of use

Negative

• None.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UPPSALA, SE / ACCESS Newswire / July 15, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB announced today that it has entered into a long-term agreement with Philips Electronics Nederland, B.V. through Philips Hospital Patient Monitoring business, a global leader in patient monitoring systems. The collaboration will explore and develop potential future solutions leveraging the companies' respective proprietary technologies. These solutions are expected to address market segments that complement Senzime's existing product portfolio and sales channels. The resulting solutions will be commercialized through Philips' global organization. Within Senzime, these solutions will be managed alongside the company's existing product portfolio and sales channels.

"This is a landmark agreement for Senzime. It will significantly expand our reach into new market segments and multiply our addressable opportunity by tens of thousands of hospitals worldwide. The commercial agreement will operate alongside our existing product portfolio and sales channels, and we expect it to accelerate the global adoption of our core technologies. Upon successful execution, I expect this relationship to become a major contributor to Senzime's revenues and earnings over the medium to long term. By leveraging our innovations through strategic industry partnerships such as this, we can access market segments that would otherwise be difficult to reach," said Philip Siberg, CEO of Senzime.

To date, Senzime's monitoring solutions have been used on more than one million patients and are marketed through the company's direct sales organization in the United States and Germany, as well as through distribution and license partners in more than 30 additional countries. The new agreement with Philips Medical Systems complements Senzime's existing commercial strategy and is expected to generate new revenue streams through Philips' extensive sales channels.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

This information is information that Senzime is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-07-15 21:00 CEST.

Attachments

Senzime and Philips Medical Systems enter development and commercialization partnership

SOURCE: Senzime

View the original press release on ACCESS Newswire

FAQ

What did Senzime (OTCQX:SNZZF) announce on July 15, 2026 regarding Philips Medical Systems?

Senzime announced a long-term development and commercialization agreement with Philips Electronics Nederland through Philips Hospital Patient Monitoring. According to Senzime, the partnership will explore and develop new solutions that combine both companies’ proprietary technologies and will be commercialized through Philips’ global sales organization.

How will the Senzime and Philips Medical Systems partnership affect commercialization of new solutions for SNZZF?

New solutions from the Senzime–Philips collaboration will be commercialized via Philips’ global organization. According to Senzime, these offerings will be managed alongside its existing portfolio and are expected to open access to complementary market segments and generate new revenue streams over time.

What market reach does Senzime expect from its agreement with Philips Hospital Patient Monitoring (SNZZF)?

Senzime expects the Philips agreement to expand its reach to tens of thousands of hospitals worldwide. According to Senzime, this significantly increases its addressable opportunity by leveraging Philips’ extensive patient monitoring customer base and international sales channels for future jointly developed solutions.

How does the Philips Medical Systems partnership fit into Senzime’s existing commercial strategy for SNZZF?

The Philips partnership is described as complementary to Senzime’s existing commercial strategy. According to Senzime, the new solutions will operate alongside its current product portfolio and sales channels, which include direct sales in the US and Germany and partners in more than 30 other countries.

What is the current footprint of Senzime’s monitoring solutions before the Philips SNZZF agreement?

Before the Philips agreement, Senzime’s monitoring solutions had been used on more than one million patients. According to Senzime, its products are sold via a direct sales organization in the United States and Germany and through distribution and license partners in over 30 additional countries.

Is the Senzime–Philips Medical Systems agreement expected to impact Senzime’s revenues and earnings (SNZZF)?

Senzime’s CEO stated that, upon successful execution, the Philips relationship is expected to become a major contributor to revenues and earnings. According to Senzime, this impact is anticipated over the medium to long term as new solutions are developed and commercialized.